ArticleProteome science2010
Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.
Article in Proteome science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Proteomic study of advanced cirrhosis based on HCV to reveal potential biomarkers.Gastroenterology and hepatology from bed to bench · 2020Article
- The Canadian Liver Meeting is a collaborative effort of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN).Canadian liver journal · 2018Article
- Identification of proteins interacting with pORF5 in the pathogenesis ofAmerican journal of translational research · 2018Article
- Glutamate contributes to alcohol hepatotoxicity by enhancing oxidative stress in mitochondria.Journal of bioenergetics and biomembranes · 2017Article
- Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection.Proteome science · 2014Article
- Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.Journal of translational medicine · 2013Article
- Opportunities in proteomics to understand hepatitis C and HIV coinfection.Future virology · 2012Article
- Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.Molecular medicine reports · 2012Article
- A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats.Proteome science · 2012Article
- Molecular serum markers of liver fibrosis.Biomarker insights · 2012Article
- Protein targets for carbonylation by 4-hydroxy-2-nonenal in rat liver mitochondria.Journal of proteomics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C virus infection, with approximately 500 million people infected with hepatitis B or C virus worldwide. Furthermore, the number of patients with non-alcoholic fatty liver disease (NAFLD) has recently increased and NAFLD can progress to cirrhosis and HCC. These chronic liver diseases are major causes of morbidity and mortality, and the identification of non-invasive biomarkers is important for early diagnosis. Recent advancements in quantitative and large-scale proteomic methods could be used to optimize the clinical application of biomarkers. Early diagnosis of HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic interventions and an improve prognosis. Furthermore, advancements of proteomic techniques contribute not only to the discovery of clinically useful biomarkers, but also in clarifying the molecular mechanisms of disease pathogenesis by using body fluids, such as serum, and tissue samples and cultured cells. In this review, we report recent advances in quantitative proteomics and several findings focused on liver diseases, including HCC, NAFLD, hepatic fibrosis and hepatitis B or C virus infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.